Transcriptional reprogramming differentiates active from inactive esr1 fusions in endocrine therapy-refractory metastatic breast cancer
AssigneeBaylor College of Medicine
InventorsMatthew J. Ellis, Xuxu Gou, Meenakshi Anurag, Jonathan T. Lei, Charles E. Foulds
Life of this patent
Estimating the term…
Abstract
Methods of treatment, methods of detection, and kits associated with ERα+ cancer, such as ERα+ breast cancer, are disclosed herein. The methods and kits disclosed herein can assist physicians in relieving patient suffering by identifying cancer estrogen receptor status, and identifying appropriate therapeutic regimens in an individualized manner.
Claims33
1-58. (canceled)
A method of treating metastatic breast cancer comprising,
- administering an effective amount of a non-ET resistant therapeutic regimen to a patient determined to have a biological sample with increased tumor cell expression of at least six genes selected from:
- ACOX2, ADCY1, ADRA2A, AFF3, AMZ1, BFSP2, BMPR1B, C14orf182, CALCR, CCDC88A, CD109, CD34, CHST8, COL3A1, CT62, CXCL12, DOK7, DSCAML1, ELOVL2, FLT4, FMN1, GATA4, GFRA1, GJA1, GREB1, GREM2, HEY2, IFITM10, IGF2, KCNH1, KRT13, MAPT, MDGA1, MPPED2, MYB, NKAIN1, NPY1R, NXPH3, OLFM1, PDZK1, PGLYRP2, PGR, PPP2R2C, PRSS56, RASGRP1, RBM24, RIMS4, ROBO3, SEMA3A, SERPINA6, SGK1, SLC47A1, SOX5, SPINK13, SPINK4, SPINK5, STC1, STC2, SUSD3, SYTL5, TFF1, TGM2, UGT3A2, VCAN, WT1, and ZNF385B.
60-63. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
80-83. (canceled)
86-115. (canceled)
A method for treating cancer in a patient, the method comprising administering a cancer therapy to the patient after determining whether the patient has a wild-type, mutant or translocated estrogen receptor alpha (ERα) protein by
- measuring a biological sample from the patient for estrogen response gene expression and/or epithelial to mesenchymal transition (EMT) gene expression, wherein the cancer therapy comprises an effective amount of a CDK 4/6 inhibitor when the patient has a mutant or translocated estrogen receptor alpha ERα protein and wherein the cancer therapy comprises an effective amount of an Endocrine Therapy (ET) and a CDK 4/6 inhibitor when the patient has a wild-type ERα protein.
117-120. (canceled)
122-163. (canceled)
165-186. (canceled)
A kit comprising oligonucleotides capable of hybridizing to, and facilitating expression level determination of, at least six genes selected from:
- ACOX2, ADCY1, ADRA2A, AFF3, AMZ1, BFSP2, BMPR1B, C14orf182, CALCR, CCDC88A, CD109, CD34, CHST8, COL3A1, CT62, CXCL12, DOK7, DSCAML1, ELOVL2, FLT4, FMN1, GATA4, GFRA1, GJA1, GREB1, GREM2, HEY2, IFITM10, IGF2, KCNH1, KRT13, MAPT, MDGA1, MPPED2, MYB, NKAIN1, NPY1R, NXPH3, OLFM1, PDZK1, PGLYRP2, PGR, PPP2R2C, PRSS56, RASGRP1, RBM24, RIMS4, ROBO3, SEMA3A, SERPINA6, SGK1, SLC47A1, SOX5, SPINK13, SPINK4, SPINK5, STC1, STC2, SUSD3, SYTL5, TFF1, TGM2, UGT3A2, VCAN, WT1, and ZNF385B.
188-191. (canceled)
193-246. (canceled)
Dependencies are inferred from the claim text.